For the status of Gal-9 expression on tumor cells, the mean time of RFS was 32.0 months (95% CI, 22.2–41.8)in the positive group, and 35.1 months (95% CI, 28.0–42.3) for patients with SCLC with negative Gal-9 status. The gene discussed is LGALS9; the disease is neoplasm.